EyePoint, Inc. — Form 8-K
Filed July 17, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 28/100
What the filing says
EyePoint Inc. settled a qui tam False Claims Act lawsuit filed by AFCE LLC alleging kickbacks to Ambulatory Surgery Centers (ASCs) for DEXYCU sales from 2019–2023. EyePoint will pay $4,657,463 to the federal government (Medicare, Medicaid, TRICARE) plus $21,519 to state Medicaid programs. The company admitted to operating an Assurance Program (reimbursing ASCs for denied claims, ~$500k paid) and distributing free DEXYCU samples; EyePoint stopped commercializing DEXYCU in the U.S. in January 2023. A 5-year Corporate Integrity Agreement imposes strict compliance monitoring, independent reviews, and potential exclusion from federal healthcare programs for material breaches.
Why this rating
Settlement ~0.73% of market cap; company already exited product. CIA overhead material but DEXYCU no longer revenue driver.
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.